This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Allogene Therapeutics (NASDAQ:ALLO), Akero Therapeutics (NASDAQ:AKRO)

Core Viewpoint - Top Wall Street analysts have revised their outlook on several key stocks, indicating a consensus rating of "Buy" for KEYS stock, with a range of price targets reflecting positive sentiment in the market [1]. Summary by Category - Analyst Consensus - The consensus rating for KEYS stock is "Buy" [1]. - Price Targets - The highest price target set by analysts is $205.00 - The lowest price target is $164.00 - The consensus price target is $184.31 [1].